Answers are grounded in this paper and cite their sources.
PURPOSE: Evaluate the clinical response to ertapenem for the treatment of bloodstream infection in patients with hypoalbuminemia compared to normoalbuminemia. METHODS: This retrospective chart review included adults with gram-negative bloodstream infections (GN-BSI) who received ertapenem and had a serum albumin level during their index hospitalization between January 2020 and May 2025. The primary outcome was a composite of 30-day mortality, bloodstream infection recurrence between 7 and 30 days from the index culture, clinical failure from day 3 of ertapenem until discharge or end of therapy (whichever came first), and 30-day readmission. RESULTS: A total of 273 patients met inclusion criteria - 146 with hypoalbuminemia (serum albumin < 2.5 g/dL) and 127 with normal levels (≥ 2.5 g/dL). Demographics were similar between cohorts, though ICU admission was more common in the hypoalbuminemia group and infection source varied between groups. The hypoalbuminemia group experienced higher rates of the composite (71.2% vs 47.2%, p < 0.001), 30-day mortality (20.6% vs 7.1%, p = 0.0016), and clinical failure (67.8% vs 45.7%, p < 0.0002). Rates of 30-day readmission and recurrence of index infection were low (∼2%) and did not differ significantly between groups. Multivariable logistic regression identified increased odds of the composite endpoint associated with hypoalbuminemia, steroid use, and higher Pitt bacteremia scores . CONCLUSION: In adults receiving ertapenem to treat susceptible GN-BSI, hypoalbuminemia was associated with increased odds of the composite outcome, 30-day mortality, and clinical failure. Larger prospective studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: